AbbVie Exec Says Co. Expects More Bolt-On Deals Rather Than Large Transformational Deal Like Allergan; Co. Has Continued Interest In Building Out Obesity Assets And Is Open To Anything With A Differentiated Profile That Could Match Its Abbv-295